New Market - June 1, 2015
Isofol Drug Receives US Patent
The use and pharmaceutical composition of Isofol Medical AB’s [6R]-methylene-tetrahydrofolate (Modufolin®), to reduce toxicity resulting from multi-targeting antifolate chemotherapy, has received a patent from the U.S. Patent and Trademark Office. Modufolin® is a folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. Isofol provided evidence demonstrating the […]
Acquisition - February 9, 2015
Isofol Seeks Marketing Partner
Isofol, a clinical stage pharmaceutical company based in Gothenburg, Sweden, has launched a global program to identify one or more strategic partners for commercialization of its Modufolin(R) chemotherapy asset. The Sage Group, which is based in Europe, the USA and Asia, has been appointed by Isofol to assist the company. Sage’s job is to identify […]
